A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Summary

This randomized, placebo-controlled, multiple ascending dose study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6807952. Patients will receive multiple weekly subcutaneous doses of RO6870952. The anticipated time on study treatment is 8 weeks.

Timeline

Start

2011-04

Primary completion

2011-09

Completion

2011-09

Drugs

Indications